Diabetic nephropathy, also referred to as diabetic kidney disease, is a common complication of diabetes. The diabetic nephropathy drug market comprises a wide variety of antidiabetic and antihypertensive drugs intended to halt the progression of kidney damage associated with diabetes. In June 2019, detailed results of the CREDENCE trial of Johnson & Johnson’s Invokana (canagliflozin) were published. By demonstrating a significant reduction in the relative risk of a renal-specific composite endpoint, Invokana became the first antidiabetic drug to demonstrate a renoprotective effect in a dedicated renal outcomes trial. Furthermore, the door has opened for sodium glucose cotransporter-2 (SGLT-2) inhibitors to be used at lower estimated glomerular filtration rate (eGFR) limits, potentially shifting treatment patterns in the diabetic nephropathy market.
GEOGRAPHY: United States
REAL-WORLD DATA: Longitudinal patient-level claims data analysis
KEY DRUGS COVERED: Invokana, Jardiance, Farxiga
KEY ANALYSIS PROVIDED: Brand/therapy usage across longitudinal patient sample; newly diagnosed patient analysis; treatment initiation and progression; line of therapy analysis; combination therapy analysis; source of business for recently treated patients; persistency and compliance analysis; product-level patient flowcharts.
PRODUCT DESCRIPTION: Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.